Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioCollaz 9 is a topical wound care and skin repair cream developed by Bion Therapeutics. It is formulated with a combination of active ingredients, including arginine (10%), carnosine (0.5%), urea (5%), collagen (2%), allantoin (0.2%), and propylene glycol (5%). The cream is designed to support the healing of chronic and acute wounds, enhance deep skin hydration, and promote tissue regeneration. Arginine and collagen support tissue repair and structural integrity, while urea and propylene glycol provide deep moisturization. Allantoin soothes skin irritation, and carnosine offers antioxidant protection against oxidative stress. BioCollaz 9 is marketed in India for advanced wound care and skin hydration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biocollaz 9.